Amesite Inc. (NASDAQ: AMST) entered into definitive agreements on April 27, 2026 for an insider‑led private placement of 418,118 shares of common stock and accompanying Series A‑1 and Series A‑2 warrants, priced at $1.435 per share. The transaction is expected to generate approximately $600,000 in gross proceeds.
The private placement is part of a broader financing effort that includes a registered direct offering and a concurrent private placement announced the day before. Together, the three offerings are projected to raise about $2.6 million in gross proceeds, providing a significant boost to the company’s balance sheet.
The primary purpose of the capital raise is to strengthen Amesite’s equity base and meet Nasdaq’s minimum‑equity requirement of $2.5 million, a deadline that expired on April 27, 2026. The company had received a deficiency letter from Nasdaq on October 28, 2025, and was granted an extension until the end of April to demonstrate compliance. The new capital will also support working‑capital needs and the continued development and commercialization of the NurseMagic™ platform in the competitive post‑acute care market.
The market reacted negatively to the announcement, citing the dilutive nature of the equity offering and the discount pricing relative to the prior day’s closing price. Investors also noted the withdrawal of a previously filed registration statement for a public offering on the same day, which added uncertainty to the company’s capital‑raising strategy.
Management emphasized confidence in the platform’s growth prospects. CEO Dr. Ann Marie Sastry said, "With an AI‑native EMR, demonstrated enterprise adoption, and a pricing model aligned with patient volumes, we are extending our platform into the core systems that post‑acute care organizations depend on." She added, "We've taken an entirely different approach from traditional EMR vendors. Our platform reimagines how post‑acute care organizations handle regulatory requirements, enabling them to leverage our AI‑powered tools to scale operations without adding staff. We specifically designed our solution to be an essential edge for customers, in a highly competitive, and demographically inevitable, market."
The financing is critical for Amesite to avoid delisting, but the company remains unprofitable, reporting a Q2 2026 earnings per share of –$0.16, a loss that underscores the need for additional capital to sustain operations and drive platform adoption.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.